{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Very Good Partial Response"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Progressive disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"To establish the disease response of myeloma patients treated with high dose melphalan, APBSCT\\& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.","groups":[{"description":"Infusing IL-2 and GM-CSF post-HCST\n\nEx-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.","id":"OG000","title":"Ex-vivo Expanded Effector Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From initiation of treatment on protocol until Day 100","title":"Assessment of Disease Response to Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}